Reduced survival in adult cystic fibrosis despite attenuated lung function decline

被引:23
|
作者
Keating, Claire [1 ]
Poor, Arrneen D. [1 ]
Liu, Xinhua [2 ]
Chiuzan, Codruta [2 ]
Backenroth, Daniel [2 ]
Zhang, Yuan [2 ]
DiMango, Emily [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Med, 622 West 168th St,Presbyterian Hosp Bldg, New York, NY 10032 USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, 722 West 168th St, New York, NY 10032 USA
关键词
Cystic fibrosis; Survival; Lung function; Adult diagnosis cystic fibrosis; LONG-TERM SURVIVORS; RESISTANT STAPHYLOCOCCUS-AUREUS; FEV1; DECLINE; DIAGNOSIS; MANIFESTATIONS; POPULATION; DISEASE; GENDER; AGE;
D O I
10.1016/j.jcf.2016.07.012
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: There is limited data on disease progression and survival in adult diagnosis cystic fibrosis (CF). This study evaluates change of lung function over time and rates of death/lung transplant in adult diagnosis CF. Methods: The CF Foundation Patient Registry was reviewed for patients diagnosed 1993-2003. Rate of FEV1 decline was calculated up to 2010 for age-groups 6-11, 12-17, and 18 and above. Kaplan Meier method was used for 10 and 15 year survival rate calculations for patients diagnosed as adults. Cox Proportional hazards models using predictors affecting disease progression and survival without transplant were run. Results: Between 1993 and 2003, 11,884 patients were diagnosed with CF, of which 2848 were ages 6 and older. Annual rate of change of FEV1% predicted over 5 years differed by diagnosis age group: 1.42% per year for ages 6-11, 2.04% for ages 12-17 and 1.13% for ages 18-65 (p < 0.0001). Pseudomonas aeruginosa infection was associated with faster rates of lung function decline in all age groups. Survival without transplant for CF patients diagnosed at 18 years were 76% and 65% by 10 and 15 years, respectively. Of adults with FEV1 of >70% predicted at diagnosis, 95% were alive without transplant at 10 years, whereas of those with FEV1 < 40% predicted at diagnosis, 31% were alive without transplant at 10 years. Conclusions: Lung function declines at a slower rate in adult diagnosis CF. However, particularly in those with low lung function at diagnosis, rates of death or transplant in adult diagnosis CF after 10 and 15 years is not negligible. (C) 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:78 / 84
页数:7
相关论文
共 50 条
  • [31] Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation
    Sethi, Jaskaran
    Bugajski, Andrew
    Patel, Kapil N.
    Davis, Nicole M.
    Wille, Keith M.
    Qureshi, Muhammad Raheel
    Banday, Mudassir M.
    Lin, Muling
    Emani, Vamsi
    Weill, David
    Tumin, Dmitry
    Hayes, Don, Jr.
    Sharma, Nirmal S.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (01) : 44 - 50
  • [32] Survival in Patients with Advanced Non-cystic Fibrosis Bronchiectasis Versus Cystic Fibrosis on the Waitlist for Lung Transplantation
    Hayes, Don, Jr.
    Kopp, Benjamin T.
    Tobias, Joseph D.
    Woodley, Frederick W.
    Mansour, Heidi M.
    Tumin, Dmitry
    Kirkby, Stephen E.
    LUNG, 2015, 193 (06) : 933 - 938
  • [33] The Presence of Exophiala dermatitidis in the Respiratory Tract of Cystic Fibrosis Patients Accelerates Lung Function Decline: A Retrospective Review of Lung Function
    Ayling-Smith, Jonathan
    Speight, Lorraine
    Dhillon, Rishi
    Backx, Matthijs
    White, Philip Lewis
    Hood, Kerenza
    Duckers, Jamie
    JOURNAL OF FUNGI, 2022, 8 (04)
  • [34] Liver and lung transplantation in cystic fibrosis: an adult cystic fibrosis centre's experience
    Sivam, S.
    Al-Hindawi, Y.
    Di Michiel, J.
    Moriarty, C.
    Spratt, P.
    Jansz, P.
    Malouf, M.
    Plit, M.
    Pleass, H.
    Havryk, A.
    Bowen, D.
    Haber, P.
    Glanville, A. R.
    Bye, P. T. P.
    INTERNAL MEDICINE JOURNAL, 2016, 46 (07) : 852 - 854
  • [35] Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis
    Ren, Clement L.
    Konstan, Michael W.
    Yegin, Ashley
    Rasouliyan, Lawrence
    Trzaskoma, Benjamin
    Morgan, Wayne J.
    Regelmann, Warren
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (04) : 293 - 299
  • [36] Predictors of deterioration of lung function in Polish children with cystic fibrosis
    Olszowiec-Chlebna, Malgorzata
    Koniarek-Maniecka, Agnieszka
    Stelmach, Wlodzimierz
    Smejda, Katarzyna
    Jerzynska, Joanna
    Majak, Pawet
    Bialasi, Monika
    Stelmach, Iwona
    ARCHIVES OF MEDICAL SCIENCE, 2016, 12 (02) : 402 - 407
  • [37] Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy
    Zhou, Grace C.
    Wang, Ziyun
    Palipana, Anushka K.
    Andrinopoulou, Eleni-Rosalina
    Miranda Afonso, Pedro
    Mcphail, Gary L.
    Siracusa, Christopher M.
    Gecili, Emrah
    Szczesniak, Rhonda D.
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [38] Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis
    Amadori, Anna
    Antonelli, Andrea
    Balteri, Ilaria
    Schreiber, Anja
    Bugiani, Massimiliano
    De Rose, Virginia
    RESPIRATORY MEDICINE, 2009, 103 (03) : 407 - 413
  • [39] Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis
    Brandt, Claudia
    Thronicke, Anja
    Roehmel, Jobst F.
    Krannich, Alexander
    Staab, Doris
    Schwarz, Carsten
    PLOS ONE, 2016, 11 (06):
  • [40] Lung function and microbiota diversity in cystic fibrosis
    Leah Cuthbertson
    Alan W. Walker
    Anna E. Oliver
    Geraint B. Rogers
    Damian W. Rivett
    Thomas H. Hampton
    Alix Ashare
    J. Stuart Elborn
    Anthony De Soyza
    Mary P. Carroll
    Lucas R. Hoffman
    Clare Lanyon
    Samuel M. Moskowitz
    George A. O’Toole
    Julian Parkhill
    Paul J. Planet
    Charlotte C. Teneback
    Michael M. Tunney
    Jonathan B. Zuckerman
    Kenneth D. Bruce
    Christopher J. van der Gast
    Microbiome, 8